Erik Dubberke, MD
Infectious Disease · Saint Louis, MONPI 1467470005
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Pfizer at 48.5% of the total. Reporting peaked in 2021 at $40,450 and has fallen 81.9% since, to $7,326 in 2025. Among infectious disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $1469.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$70K
- Merck$25K
- Astrazeneca UK Limited$15K
- Ferring Pharmaceuticals Inc.$14K
- Sanofi Pasteur Inc.$10K
- AstraZeneca$4K
- plus $5K from 5 others
Across 106 payments — averaging $8227.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$706K
- AstraZeneca$87K
- Cepheid$64K
- Seres Therapeutics, Inc.$15K
What the payments were for
- Consulting fees$84,89359%
- Speaking & faculty fees$47,45033%
- Travel & lodging$9,8287%
- Food & beverage$1,7741%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 27 | $69,812 |
| Merck | 24 | $25,204 |
| Astrazeneca UK Limited | 9 | $15,374 |
| Ferring Pharmaceuticals Inc. | 13 | $14,168 |
| Sanofi Pasteur Inc. | 9 | $10,097 |
| AstraZeneca | 8 | $4,033 |
| GSK | 2 | $2,200 |
| Ferring International Center SA | 1 | $1,575 |
| Abbott | 1 | $800 |
| Idorsia Pharmaceuticals US Inc | 2 | $683 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- C DIFFICILE$7,570
- ZINPLAVA$7,324
- REBYOTA$6,129
- NO PRODUCT DISCUSSED$863
How this compares
$143,978 in reported general payments places this provider in the 95th percentile of 177 infectious disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vancomycin Hcl | 22 | $1,796 |
| CeftriaxoneCeftriaxone Sodium | 16 | $890 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Saint Louis
- Robert BelsheSaint Louis$382K
- Rupa PatelSaint Louis$96K
- Michael DiamondSaint Louis$44K
- Andrej SpecSaint Louis$26K
- William PowderlySaint Louis$20K
- Elvin GengSaint Louis$15K
- Matifadza HlatshwayoSaint Louis$11K
- Bernard CaminsSaint Louis$11K
- Joseph CherabieSaint Louis$9K
- Rachel PrestiSaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.